Key facts
- 52-week range (closes)
- $9.93 – $18.27 Lowest close Oct 14, 2025, highest Sep 28, 2026; 251 daily closes to Oct 13, 2026 from Dalsna Finance's price archive
- Fiscal year ends
- December Fiscal 2025 ended Dec 31, 2025, from SEC filings
- In the S&P 500 since
- Apr 23, 2004 · All S&P 500 changes
Viatris (VTRS) is trading up at $18.42 (+0.88%) on NYSE/NASDAQ, as of the latest quote. It is a S&P 500 constituent in the Health Care sector.
Viatris revenue & net income history (FY2018–FY2025)
| FY2018Dec 2018 | FY2019Dec 2019 | FY2020Dec 2020 | FY2021Dec 2021 | FY2022Dec 2022 | FY2023Dec 2023 | FY2024Dec 2024 | FY2025Dec 2025 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $11.4B | $11.5B | $11.9B | $17.9B | $16.3B | $15.4B | $14.7B | $14.3B |
| Growth (year over year) | — | +0.6% | +3.9% | +49.7% | −9.1% | −5.1% | −4.5% | −3.0% |
| Gross profit | $4.00B | $3.90B | $3.80B | $5.58B | $6.50B | $6.44B | $5.62B | $5.01B |
| Gross margin | 35.0% | 33.9% | 31.8% | 31.2% | 40.0% | 41.7% | 38.2% | 35.1% |
| Operating income | $905.6M | $715.5M | −$210.8M | −$34.0M | $1.61B | $766.2M | $10.1M | −$2.66B |
| Operating margin | 7.9% | 6.2% | −1.8% | −0.2% | 9.9% | 5.0% | 0.1% | −18.6% |
| Net income | $352.5M | $16.8M | −$669.9M | −$1.27B | $2.08B | $54.7M | −$634.2M | −$3.51B |
| Net margin | 3.1% | 0.1% | −5.6% | −7.1% | 12.8% | 0.4% | −4.3% | −24.6% |
| EPS (diluted) | $0.68 | $0.03 | −$1.11 | −$1.05 | $1.71 | $0.05 | −$0.53 | −$3.00 |
| Balance sheet | ||||||||
| Cash and equivalents | $388.1M | $475.6M | $844.4M | $701.2M | $1.26B | $991.9M | $734.8M | $1.32B |
| Total assets | — | $31.3B | $61.6B | $54.8B | $50.0B | $47.7B | $41.5B | $37.2B |
| Total liabilities | — | $19.4B | $38.6B | $34.4B | $28.9B | $27.2B | $22.9B | $22.5B |
| Long-term debt | — | $11.2B | $22.4B | $19.7B | $18.0B | $16.2B | $14.0B | $12.5B |
| Shareholders' equity | $12.2B | $0 | $23.0B | $20.5B | $21.1B | $20.5B | $18.6B | $14.7B |
| Cash flow | ||||||||
| Operating cash flow | $2.34B | $1.80B | $1.23B | $3.02B | $3.00B | $2.90B | $2.30B | $2.32B |
| Capital expenditure | $252.1M | $213.2M | $243.0M | $457.2M | $406.0M | $377.0M | $326.0M | $378.8M |
| Free cash flow | $2.09B | $1.59B | $988.8M | $2.56B | $2.59B | $2.52B | $1.98B | $1.94B |
| Share buybacks | $432.0M | $0 | $0 | $0 | $0 | $250.0M | $250.0M | $500.5M |
| Q3 FY24Sep 2024 | Q4 FY24†Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25†Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 | |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $3.75B | $3.53B | $3.25B | $3.58B | $3.76B | $3.70B | $3.52B | $3.76B |
| Growth (year over year) | −4.8% | −8.1% | −11.2% | −5.6% | +0.2% | +5.0% | +8.1% | +4.9% |
| Gross profit | $1.46B | $1.22B | $1.16B | $1.33B | $1.37B | $1.15B | $1.16B | $1.46B |
| Gross margin | 38.9% | 34.4% | 35.7% | 37.2% | 36.5% | 31.0% | 32.9% | 38.8% |
| Operating income | $225.9M | −$179.8M | −$2.88B | $233.0M | $178.8M | −$192.7M | −$79.7M | $6.30M |
| Operating margin | 6.0% | −5.1% | −88.6% | 6.5% | 4.8% | −5.2% | −2.3% | 0.2% |
| Net income | $94.8M | −$516.5M | −$3.04B | −$4.60M | −$128.2M | −$340.1M | $176.4M | −$118.8M |
| Net margin | 2.5% | −14.6% | −93.5% | −0.1% | −3.4% | −9.2% | 5.0% | −3.2% |
| EPS (diluted) | $0.08 | −$0.43 | −$2.55 | $0.00 | −$0.11 | −$0.34 | $0.15 | −$0.10 |
| Balance sheet | ||||||||
| Cash and equivalents | $1.88B | $734.8M | $755.0M | $566.4M | $975.3M | $1.32B | $1.80B | $886.5M |
| Total assets | $44.8B | $41.5B | $38.5B | $38.4B | $37.9B | $37.2B | $36.8B | $35.0B |
| Total liabilities | $25.0B | $22.9B | $22.8B | $22.8B | $22.7B | $22.5B | $22.2B | $20.8B |
| Long-term debt | $14.3B | $14.0B | $14.2B | $12.8B | $12.5B | $12.5B | $12.4B | $11.6B |
| Shareholders' equity | $19.8B | $18.6B | $15.7B | $15.6B | $15.2B | $14.7B | $14.7B | $14.3B |
| Cash flow | ||||||||
| Operating cash flow | $826.5M | $482.7M | $535.5M | $219.7M | $744.9M | $815.8M | $388.3M | $381.8M |
| Capital expenditure | $77.0M | $140.4M | $42.6M | $52.9M | $86.8M | $196.5M | $39.9M | $52.8M |
| Free cash flow | $749.5M | $342.3M | $492.9M | $166.8M | $658.1M | $619.3M | $348.4M | $329.0M |
| Share buybacks | $0 | $0 | $175.4M | $175.0M | $67.9M | $82.2M | $0 | $150.0M |
From Viatris's 10-K and 10-Q filings with the SEC; its fiscal year ends in December. Each period shows the latest figure the company has reported for it, including restatements. Net margin is our own calculation from those reported figures (net income ÷ revenue); it is left blank where revenue is zero or missing. † Quarter derived from the company's year-to-date or full-year totals. Filings on SEC EDGAR →
Viatris vs the Health Care sector and the S&P 500
Viatris's latest reported figures next to the median of the other 59 S&P 500 Health Care companies and of the other 502 S&P 500 companies; each median is taken over the companies with a comparable figure (counts in the footnote). A median is the middle value, not an average, so one very large company does not move it.
| Measure | Viatris | Health Care (59 other S&P 500 companies) | S&P 500 (502 other companies) |
|---|---|---|---|
| Revenue growth, latest fiscal year | −3.0% | +7.2% | +7.0% |
| Net margin, latest fiscal year | −24.6% | 13.1% | 13.0% |
| Dividend per share, latest fiscal year | $0.48 | $2.48 | $2.40 |
| Share price change, 1 year | +77.1% | +19.8% | +5.6% |
Viatris: fiscal year ended December 2025, from its 10-K and 10-Q filings with the SEC. Medians computed October 20, 2026 from each company's latest annual filing (fiscal years ending between July 2025 and September 2026) and our price archive. Prices for every company, Viatris included, are the last regular-session prices of October 19, 2026; the 1-year change compares that price with each company's last close on or before October 20, 2025. Net margin and price change are our calculations from reported figures. Each median counts only the companies with a comparable figure (sector / S&P 500): revenue growth 59/496, net margin 59/496, dividend per share 32/349, 1-year price change 59/490; the reasons below can overlap. 12 are left out of the price figure because our archive holds no comparable close for them; dividend medians are among the 32 sector and 349 S&P 500 companies reporting a per-share dividend. The S&P 500 price figure is the middle company's change, not the index's return.
About Viatris
Viatris Inc. is an American global pharmaceutical and healthcare corporation headquartered in Canonsburg, Pennsylvania. The corporation was formed through the merger of Mylan and Upjohn, a legacy division of Pfizer, on November 16, 2020.
- Headquarters
- Canonsburg, Pennsylvania From SEC filings, Oct 2026
Recent News (20)
-
Viatris receives FDA approval for presbyopia treatment
Viatris receives FDA approval for presbyopia treatment
-
Viatris Receives U.S. FDA Approval for RYZUMVI® for the Treatment of Presbyopia PITTSBURGH, Oct. 16, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare company, today announced that the U.S. Food and Drug Administration (FDA) has approved RYZUMVI® (phentolamine…
-
Jefferies downgrades Pacira Pharmaceuticals stock rating on Viatris deal
Jefferies downgrades Pacira Pharmaceuticals stock rating on Viatris deal
-
4 stocks to watch on Thursday: AVGO, PLTR, AMZN, and VTRS (SP500:) 4 stocks to watch on Thursday: AVGO, PLTR, AMZN, and VTRS (SP500:) Seeking Alpha
-
Viatris Agrees to Acquire Pacira BioSciences, Advancing Its Innovative Medicines Strategy and Becoming a Leader in Non-Opioid Pain Therapies Adds Two Marketed, Patent-Protected, High-Margin Medicines in the U.S., EXPAREL® and ZILRETTA®, and Expects to Expand the Products' Reach Across Selected Markets Within Its International Infrastructur…
-
-
Viatris (VTRS) Wins Japan WAKIX Approval. Can it Build a Meaningful Specialty Business?
Viatris (VTRS) Wins Japan WAKIX Approval. Can it Build a Meaningful Specialty Business?
-
Viatris receives Japan approval for sleep disorder drug Wakix
Viatris receives Japan approval for sleep disorder drug Wakix
-
Viatris Announces Approval of WAKIX® (Pitolisant) in Japan, a First-in-Class Treatment for Narcolepsy and Excessive Daytime Sleepiness Associated With Obstructive Sleep Apnea Syndrome Approval Addresses High Unmet Medical Need and Further Advances Viatris' Innovative Portfolio in Japan PITTSBURGH, Sept. 16, 2026 /PRNewswire/ -- Viatris Inc. (Nasdaq: VTRS), a global healthcare compa…
-
Cavendish reiterates 'buy' rating on Shield Therapeutics after US deal with Viatris
Cavendish reiterates 'buy' rating on Shield Therapeutics after US deal with Viatris
-
Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine?
Viatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine?
-
Viatris (VTRS) Q2 2026 Earnings Call Transcript
Viatris (VTRS) Q2 2026 Earnings Call Transcript
-
Viatris Q2 2026 slides: strong results lift guidance amid H2 headwinds
Viatris Q2 2026 slides: strong results lift guidance amid H2 headwinds
-
-
Is Wall Street Bullish or Bearish on Viatris Stock? Is Wall Street Bullish or Bearish on Viatris Stock?
-
-
-
Viatris stock hits 52-week high at $17.68
Viatris stock hits 52-week high at $17.68
-
Merck signs licensing deals with companies including Viatris for new HIV pill Merck signs licensing deals with companies including Viatris for new HIV pill Seeking Alpha
-
Viatris’ Quarterly Earnings Preview: What You Need to Know Viatris’ Quarterly Earnings Preview: What You Need to Know
More Health Care stocks
- UHS Universal Health Services
- UNH UnitedHealth Group
- VEEV Veeva Systems
- VRTX Vertex Pharmaceuticals
- WAT Waters Corporation
- WST West Pharmaceutical Services
- ZBH Zimmer Biomet
- ZTS Zoetis